What does €5–10 million buy in European life sciences real estate?
France and Ireland lead the €5–10 million bracket, largely concentrated in point of care and R&D assets across Europe.
4 min read
Investment
Stay updated on the latest investment and market developments in life sciences real estate. Explore key funding trends, major transactions, and market insights shaping the industry's future. Whether you're an investor, developer, or industry professional, this page delivers essential updates on deals, acquisitions, and emerging opportunities in the life sciences property market.
16 posts
Reverse conversions: when science facilities find new purpose
Converting former science facilities to new uses offers investors portfolio protection against tenant risk while unlocking new income streams.
3 min read
Why life sciences real estate deserves a strategic place in professional portfolios
Life sciences real estate offers institutional investors resilient returns, portfolio diversification, and alignment with healthcare megatrends.
5 min read
paid
Medtech companies and their real estate
European medtech companies navigate complex real estate decisions across innovation clusters, balancing flexibility needs with regulatory requirements.
5 min read
paid
Niche sector, strong momentum: life sciences' growing share of the UK commercial property market
Life sciences real estate is a specialised segment expanding at a speed that outpaces most traditional property sectors.
4 min read
paid
How CROs and CDMOs navigate real estate decisions
Life science contract organisations balance real estate ownership (73 per cent) vs leasing (27 per cent) based on financial, operational, and strategic considerations.
5 min read